ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2567 • 2014 ACR/ARHP Annual Meeting

    Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab

    Xenofon Baraliakos1, Kay-Geert A. Hermann2, Stephen Xu3, Benjamin Hsu3 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose Using data from GO-RAISE, we analyzed correlations between serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels, radiographic progression and inflammation as…
  • Abstract Number: 2566 • 2014 ACR/ARHP Annual Meeting

    Spinal Mobility in the Cervical and the Lumbar Spine Correlates with Magnetic Resonance Imaging Findings in Patients with Ankylosing Spondylitis

    Xenofon Baraliakos1, Kay-Geert A. Hermann2, Stephen Xu3, Benjamin Hsu3 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose Spinal mobility, as assessed by the Bath Ankylosing Spondylitis Metrology Index, BASMI, and imaging findings have been reported to correlate on the group level.…
  • Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting

    The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis

    Michael J. Nissen1, Adrian Ciurea2, Juerg Bernhard3, Rudiger Muller4, Giorgio Tamborrini5, Martin Toniolo6, Cem Gabay7 and Axel Finckh1, 1Rheumatology, Geneva University Hospital, Geneva, Switzerland, 2Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, 3Rheumatology, Solothurn Hospital, Solothurn, Switzerland, 4Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 5Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, 6Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, 7University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland

    Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
  • Abstract Number: 2562 • 2014 ACR/ARHP Annual Meeting

    The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis  and ankylosing spondylitis; results from Turkbio Registry

    Ismail Sari1, Umut Kalyoncu2, Ahmet Mesut Onat3, Omer Nuri Pamuk4, Omer Karadag2, Bunyamin Kisacik3, Niels Steen Krogh5, Soner Şenel6, Fatih Saritaş7, Ihsan Ertenli2, Sedat Kiraz2, Pinar Cetin1, Fatos Onen1 and Nurullah Akkoc1, 1Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 2Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, 3Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 4Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, 5Consultant, ZiteLab Aps, Copenhagen, Denmark, 6Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, 7Rheumatology, Trakya University School of Medicine, Edirne, Turkey

    Background/Purpose Three different anti–tumor necrosis factor α (anti-TNFα) drugs (infliximab, etanercept, and adalimumab) are approved for patients with rheumatoid arthritis (RA) and particular ankylosing spondylitis…
  • Abstract Number: 2563 • 2014 ACR/ARHP Annual Meeting

    The Distribution of Inflammatory Lesions in the Anterior and Posterior Structures of the Spine in Patients with Active Ankylosing Spondylitis and the Effect of TNF-α-Blockade

    Xenofon Baraliakos1, Kay-Geert A. Hermann2, Stephen Xu3, Benjamin Hsu3 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Janssen Research & Development, LLC., Spring House, PA

    Background/Purpose Magnetic resonance imaging (MRI) is a key tool for the assessment of inflammatory lesions used for diagnosis and the monitoring of treatment effects in…
  • Abstract Number: 2564 • 2014 ACR/ARHP Annual Meeting

    Ileocolonoscopic Findings in the Korean Patients with Ankylosing Spondylitis

    Soo Min Ahn, Bin Yoo, Chang-Keun Lee, Yong-Gil Kim, Seokchan Hong, Seung-Hyeon Bae and Doo-Ho Lim, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

    Background/Purpose: The prevalence of concurrent Ankylosing spondylitis (AS) and inflammatory bowel disease, either Crohn's disease (CD) or Ulcerative colitis (UC), is estimated at 5-10%. Up…
  • Abstract Number: 2561 • 2014 ACR/ARHP Annual Meeting

    Low Cardio-Respiratory Fitness Is Associated with Increased Arterial Stiffness in Patients with Ankylosing Spondylitis

    Inger Jorid Berg1, Anne Grete Semb2, Silje H. Sveaas3,4, Camilla Fongen3, Désirée van der Heijde3,5, Tore K. Kvien3, Hanne Dagfinrud3 and Sella A. Provan3, 1Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Health Sience, University of Oslo, Oslo, Norway, 5Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose We have previously shown that patients with ankylosing spondylitis (AS) have lower cardio-respiratory fitness (CRF) than population controls. CRF is inversely associated to risk…
  • Abstract Number: 2560 • 2014 ACR/ARHP Annual Meeting

    Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

    Desiree van der Heijde1, Juergen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Endokrinologikum, Berlin, Germany, 4Allee De La Recherche 60, UCB Pharma, Anderlecht, Belgium, 5University of California San Diego, La Jolla, CA

    Background/Purpose Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). Previous…
  • Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting

    Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis

    Alan N. Baer1, Michelle Petri2, David Fiorentino3, Tao Wang4, Jungsan Sohn4, Antony Rosen1 and Livia Casciola-Rosen5, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, 4Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, 5Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…
  • Abstract Number: 2538 • 2014 ACR/ARHP Annual Meeting

    Ultrasound-Guided Core Needle Biopsy of the Major Salivary Glands Is a Safe and Useful Diagnostic Tool in the Evaluation of Suspected or Established Sjögren’s Syndrome

    Anand Narayan1, Thomas Grader-Beck2, Julius Birnbaum3, Jean Kim4, Qing Kay Li5, Deborah Belchis5, Joel Fradin1 and Alan N. Baer6, 1Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 2Medicine Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 5Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 6Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Ultrasound-guided core needle biopsy (CNB) has greater inherent risks than fine-needle aspiration for the diagnosis of major salivary gland neoplasms, but provides tissue for…
  • Abstract Number: 2537 • 2014 ACR/ARHP Annual Meeting

    Diagnostic Accuracies of Sialography and Salivary Ultrasonography in Sjogren’s Syndrome Patients: A Meta-Analysis

    Young Ho Lee1 and Gwan Gyu Song2, 1Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, 2Div of Rheum, Dept of Int Medicine, Guro Hospital, Korea Univ College of Medicine, Seoul, South Korea

    Background/Purpose Ultrasonography (US) may come to replace conventional invasive examinations in clinical practice. However, the diagnostic accuracy of salivary US has not been clearly compared…
  • Abstract Number: 2536 • 2014 ACR/ARHP Annual Meeting

    The Sjögren’s Syndrome Responder Index, a Data-Driven Combined Endpoint, Could Detect Biologics Efficacy

    Divi Cornec1, Valerie Devauchelle-Pensec2, Xavier Mariette3, Sandrine Jousse-Joulin4, Jean-Marie Berthelot5, Aleth Perdriger6, Xavier Puéchal7, Véronique le Guern8, Jean Sibilia9, Jacques Gottenberg10, Laurent Chiche11, Eric Hachulla12, Pierre-Yves Hatron13, Vincent Goëb14, Gilles Hayem15, Jacques Morel16, Charles Zarnitsky17, Jean Jacques Dubost18, Raphaèle Seror19, Jacques-Olivier Pers20, Emmanuel Nowak21 and Alain Saraux22, 1Department of rheumatology and unit of immunology, Brest Occidentale University, Brest, France, 2Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, 3rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, 4Rheumatology, CHU Brest, Brest, France, 5Rheumatology, CHU Nantes (Nantes University Hospital), Nantes, France, 6Rhumatologie, Rennes, France, 7National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 8Department of Internal Medicine, Hôpital Cochin, Paris, France, 9Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 10Rheumatology, Strasbourg University Hospital, Strasbourg, France, 11147 Boulevard Baille, CHU Marseille, Marseille, France, 12Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, 13CHU Lille, Lille, France, 14Rheumatology, Amiens University Hospital, Amiens, France, 15CHU Bichat, Paris, France, 16Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 17Rheumatology, Le Havre General Hospital, Le Havre, France, 18Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, 19Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, 20CHU Brest, Brest, France, 21CIC, CHU Brest, Brest, France, 22Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France

    Background/Purpose Efficacy of rituximab remains debated in primary Sjögren’s syndrome (pSS), but that could be partly due to the absence of validated endpoint. To determine…
  • Abstract Number: 2535 • 2014 ACR/ARHP Annual Meeting

    Performance of the Ocular Staining Score (OSS) Vs. the Van Bijsterveld Score in the Assessment of Sjögren’s Syndrome-Related Keratoconjunctivitis Sicca

    Astrid Rasmussen1, Michael Brown1, Donald U Stone2, Keith Earley3, Kimberly S. Hefner4, Lida Radfar5, David M. Lewis6, Stephen Young6, Nelson L. Rhodus7, Barbara M. Segal8, Christopher J. Lessard9, Courtney G. Montgomery10, R. Hal Scofield11 and Kathy L. Sivils12, 1Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Dean McGee Eye Institute, Oklahoma City, OK, 3US Air Force, Oklahoma City, OK, 4Hefner Eye Care and Optical Center, Oklahoma City, OK, 5College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 6College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 7University of Minnesota, Minneapolis, MN, 8Rheumatology, Hennepin County Medical Center, Minneapolis, MN, 9825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK, 10Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 12Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Sjögren’s syndrome (SS) is a complex autoimmune disorder characterized by xerostomia and xerophthalmia due to exocrine gland dysfunction. There is no single diagnostic test…
  • Abstract Number: 2534 • 2014 ACR/ARHP Annual Meeting

    Ocular Surface Temperature in Early Sjogren’s Syndrome and Established Disease

    Andreea Coca1, Ranjini Kottaiyan2, Mircea Coca3, Debbie Campbell4, Holly Hindman2 and James Aquavella2, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Ophtalmology, University of Rochester, Rochester, NY, 3Ophtalmology, University of Texas Medical Branch, Galveston, TX, 4Allergy, Immunology and Rheumatology, Univerity of Rochester, Rochester, NY

    Background/Purpose Due to a variety of factors it is challenging to make a definite diagnosis in the early stages of Sjögren’s syndrome (SS). The ocular…
  • Abstract Number: 2553 • 2014 ACR/ARHP Annual Meeting

    Compromised Volumetric Bone Density, Bone Microarchitecture and Bone Strength in Patients with Ankylosing Spondylitis: High-Resolution Peripheral Quantitative Computerized Tomography (HRpQCT) Based Study

    Nisha Nigil Haroon1, Eva Szabo2, Janet Raboud3, Ammepa Anton4, Robert Josse1, Robert D. Inman1 and Angela Cheung1, 1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Osteoporosis Program, UHN, TOronto, ON, Canada, 3Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 4Rheumatology, University Health Network, Toronto, ON, Canada

    Background/Purpose Patients with ankylosing spondylitis (AS) have high fracture risk. BMD, bone microarchitecture and strength determine fracture risk. However, in AS, DXA-based BMD measurements of…
  • « Previous Page
  • 1
  • …
  • 1880
  • 1881
  • 1882
  • 1883
  • 1884
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology